What is Orforglipron?
Orforglipron is a nonpeptide small-molecule GLP-1 receptor agonist. It belongs to a different chemical class from injectable peptide GLP-1 agonists despite targeting the same receptor family.
Mechanism & research focus
GLP-1 receptor activation is investigated in glucose regulation and energy-intake pathways. Clinical effects depend on the characterized molecule and formulation, rather than the generic label 'capsulated GLP.'
What the research covers
The 2025 ATTAIN-1 phase 3 trial reported greater weight reduction than placebo over 72 weeks. A separate 2025 phase 3 study in early type 2 diabetes reported greater glycated-hemoglobin reduction. Gastrointestinal adverse events and treatment discontinuations occurred.
What remains uncertain
Weight and glycemic trials answer distinct questions and do not establish every long-term clinical outcome. Published results concern controlled study products. They do not confirm the identity, bioavailability or clinical interchangeability of a separately marketed research capsule.
The evidence label describes the linked research, not the suitability of a catalog product for use in people. Formulation, identity, purity, and measured content must be assessed separately.
Sources & studies
Orforglipron for obesity treatment: ATTAIN-1 ↗
72-week placebo-controlled obesity study, with efficacy and adverse-event reporting.
Orforglipron in early type 2 diabetes ↗
ACHIEVE-1: glycemic and weight outcomes in an early type 2 diabetes population.
Read the full paper for its design, controls and limitations. A source link is not a claim that its tested material matches a DA formulation.
Catalog formats & documentation
Formats grouped by compound identity. Availability and batch documentation remain on Disguised Alpha.